Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 382

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 382
---
, counseling and direction to ParentCo’s management. The ParentCo Board will meet on a regular basis and additionally as required.

In accordance with the terms of the ParentCo Bylaws, which will be effective upon the consummation of the Business Combination, the ParentCo Board may establish the authorized number of directors from time to time by resolution. The ParentCo Board will consist of three (3) members upon the consummation of the Business Combination. In accordance with the ParentCo Certificate of Incorporation, which will be effective upon the consummation of the Business Combination, the ParentCo Board will be divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. ParentCo’s directors will be divided among the three classes as follows:

•

the Class I director will be Mr. Nicholas Fernandez and Dr. Ji Yeon Baek, with a term that will expire at the annual meeting of stockholders to be held in 2026;

•

the Class II director will be Dr. Eun Sook Lee, with a term that will expire at the annual meeting of stockholders to be held in 2027; and

•

the Class III director will be Mr. Chris Kim, with a term that will expire at the annual meeting of stockholders to be held in 2028.

Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors.

<div align='center'>209</div>

TABLE OF CONTENTS

The division of the ParentCo Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.

#### Director Independence
As a result of ParentCo’s common stock being listed on Nasdaq following the consummation of the Business Combination, it will be required to comply with the applicable rules of such exchange in determining whether a director is independent. Prior to the completion of this Business Combination, the parties undertook a review of the independence of the individuals named above and have determined that each of Dr. Eun Sook Lee, Dr. Ji Yeon Baek and Nicholas Fernandez qualifies as “independent” as defined under the applicable Nasdaq rules.

#### Role of the Board in Risk Oversight
Upon the consummation of the Business Combination, one of the